Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of Zhejiang University. Science. B ; (12): 611-627, 2020.
Artigo em Inglês | WPRIM | ID: wpr-1010541

RESUMO

Immunoglobulin Y (IgY) is an effective orally administered antibody used to protect against various intestinal pathogens, but which cannot tolerate the acidic gastric environment. In this study, IgY was microencapsulated by alginate (ALG) and coated with chitooligosaccharide (COS). A response surface methodology was used to optimize the formulation, and a simulated gastrointestinal (GI) digestion (SGID) system to evaluate the controlled release of microencapsulated IgY. The microcapsule formulation was optimized as an ALG concentration of 1.56% (15.6 g/L), COS level of 0.61% (6.1 g/L), and IgY/ALG ratio of 62.44% (mass ratio). The microcapsules prepared following this formulation had an encapsulation efficiency of 65.19%, a loading capacity of 33.75%, and an average particle size of 588.75 μm. Under this optimum formulation, the coating of COS provided a less porous and more continuous microstructure by filling the cracks on the surface, and thus the GI release rate of encapsulated IgY was significantly reduced. The release of encapsulated IgY during simulated gastric and intestinal digestion well fitted the zero-order and first-order kinetics functions, respectively. The microcapsule also allowed the IgY to retain 84.37% immune-activity after 4 h simulated GI digestion, significantly higher than that for unprotected IgY (5.33%). This approach could provide an efficient way to preserve IgY and improve its performance in the GI tract.


Assuntos
Ácido Algínico/química , Quitina/química , Quitosana , Preparações de Ação Retardada , Digestão , Composição de Medicamentos , Liberação Controlada de Fármacos , Trato Gastrointestinal/metabolismo , Imunoglobulinas/metabolismo , Oligossacarídeos
2.
Chinese Journal of Medical Genetics ; (6): 177-180, 2003.
Artigo em Chinês | WPRIM | ID: wpr-248466

RESUMO

<p><b>OBJECTIVE</b>To investigate the mutation characteristics of spastin gene in Chinese patients with hereditary spastic paraplegia (HSP) and thus provide a basis for the gene diagnosis of HSP.</p><p><b>METHODS</b>Mutation of spastin gene was screened by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) combined with DNA direct sequencing in 31 unrelated affected HSP individuals in China, of whom 22 were from autosomal dominant families and 9 were sporadic HSP patients. Co-segregation analysis was carried out after the finding of abnormal SSCP bands.</p><p><b>RESULTS</b>Six cases were found to have abnormal SCP bands, and among them, two missense mutations (T1258A, A1293G in exon 8) and one deletion mutation (1667delACT or 1668delCTA or 1669delTAC in exon 14) were found and all of them were not reported previously. They were all co-segregated with the disease and were localized within the functional domain of spastin gene. Besides, T1258A was seen in two unrelated families.</p><p><b>CONCLUSION</b>The mutation rate (18.2%) in autosomal dominant HSP in Chinese patients is comparatively low. Point mutation is the major mutation type and exon 8 may be the mutation hot spot.</p>


Assuntos
Feminino , Humanos , Masculino , Adenosina Trifosfatases , Genética , Povo Asiático , Genética , China , Éxons , Íntrons , Mutação , Mutação de Sentido Incorreto , Linhagem , Paraplegia Espástica Hereditária , Genética , Espastina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA